中国临床药理学杂志2025，Vol.41Issue(19)：2701-2705,5.DOI:10.13699/j.cnki.1001-6821.2025.19.001
甲磺酸倍他司汀联合奥拉西坦对后循环缺血性眩晕的临床研究
Clinical trial of betahistine mesylate combined with oxiracetam in treating posterior circulation ischemic vertigo
摘要
Abstract
Objective To investigate the clinical efficacy of betahistine mesylate combined with oxiracetam in the treatment of patients with posterior circulation ischemic vertigo(PCIV).Methods This prospective study included 80 patients with PCIV who were treated at our hospital between June 2022 and June 2024.The patients were randomly assigned into two groups:the observation group(40 cases,treated with betahistine combined with oxiracetam)and the control group(40 cases,treated with betahistine monotherapy).After two weeks of treatment,the following were assessed:vertigo symptom scores[Electronystagmography(ENG)score,Visual Vertigo Analogue Scale(VVAS),and Sheikh Control Scale(SCS)],imaging indicators,and serum-related factors.Results After treatment,the nystagmogram score and Visual Vertigo Analog Scale(VVAS)score of the observation group were(3.08±0.86)and(37.13±3.26)points,respectively,which decreased significantly,while the Situational Vertigo Scale(SCS)score was(82.55±7.89)points,which increased significantly(P＜0.05).The average blood flow velocities of the basilar artery and vertebral artery in the observation group were significantly higher than those in the control group(P＜0.05).The serum levels of endothelin-1(ET-1)and platelet-derived growth factor-BB(PDGF-BB)decreased,and the level of nerve growth factor(NGF)increased,with the observation group showing a better effect than the control group(P＜0.05).The observation group experienced 2 cases of nausea and vomiting,2 cases of rash,2 cases of drowsiness,and 4 cases of dizziness,while the control group had 1 case of nausea and vomiting,1 case of rash,and 1 case of dizziness,with no drowsiness reported.The incidence of adverse reactions was higher in the observation group than in the control group(x2=4.501,P=0.034)(P＜0.05).Conclusion Betahistine mesylate combined with oxiracetam significantly improves symptoms in patients with PCIV,enhances hemodynamics,and modulates serum factors,demonstrating promising clinical application potential.关键词
甲磺酸倍他司汀注射液/奥拉西坦片/后循环缺血性眩晕/血流动力学/神经保护Key words
betahistine mesylate injection/oxiracetam tablet/posterior circulation ischemic vertigo/hemodynamics/neuroprotection分类
医药卫生引用本文复制引用
LIU Rui-hong,HE Yu-fan,ZHANG Xiao-dong..甲磺酸倍他司汀联合奥拉西坦对后循环缺血性眩晕的临床研究[J].中国临床药理学杂志,2025,41(19):2701-2705,5.基金项目
四川省科技计划基金资助项目(2022ZYZFSY01) （2022ZYZFSY01）
